Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University Hospital, Marseille | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the production of multiple autoantibodies. Antibodies against Ficolin-3 were previously identified in the sera of some SLE patients, but their prevalence and significance have not been yet investigated. The aims of this study were to determine the prevalence of anti-ficolin-3 antibodies among SLE patients and to investigate their potential as diagnostic and/or prognostic biomarkers in SLE.
In this retrospective study, clinical data were obtained from medical files and blood samples were selected from preexisting biological collection. SLE patients (n=165) were informed and did not objected, they were matched to healthy controls (n=48). Disease activity was determined according to the SLEDAI score. Anti-ficolin-3, anti-dsDNA and anti-C1q antibodies levels were measured in sera by ELISA. First, a highly significant difference was found in the anti-ficolin-3 levels between SLE patients and healthy subjects. Anti-ficolin-3 antibodies were detected as positive in 58 of 165 (35%) SLE patients. The titer of anti-ficolin-3 antibodies was correlated with the SLEDAI score (p<0.0001). The presence of anti-ficolin-3 antibodies was associated with anti-C1q and anti-dsDNA antibodies. Regarding associations with clinical manifestations, only the presence of active lupus nephritis was significantly associated with the presence of anti-ficolin-3 antibodies (p=0.0001). This association with renal involvement was higher with anti-ficolin-3 antibodies than with other auto-antibodies. Interestingly, the combination of anti-ficolin-3 and anti-C1q antibodies demonstrated higher specificity than any other traditional biomarker.
These results suggest that anti-ficolin-3 could be useful for the diagnosis of active nephritis in SLE patients.
For this retrospective study, a brief summary should be enough.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| SLE patients | 165 SLE patients. Subgroup : 77 with active lupus and 88 in disease remission. in the active subgroup : 36 with lupus nephritis and 41 without. Biological analysis were performed. |
| |
| healthy patients | 48 healthy patients. Biological analysis were performed. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Biological analysis | Other | Biological analysis :
|
|
| Measure | Description | Time Frame |
|---|---|---|
| Anti-ficolin-3 antibodies presence in SLE patients | Anti-ficolin-3 antibodies in SLE patients, considered positive if superior than 70 arbitrary units. This study have a single visit approach with serum collection so every outcome is measured at T0, which is the only visit for the patient. | measured at day of inclusion = T0. |
| Measure | Description | Time Frame |
|---|---|---|
| Correlation of anti-ficolin-3 antibodies with anti-DNA antibodies in SLE patients | This study have a single visit approach with serum collection so every outcome is measured at T0, which is the only visit for the patient. | measured at day of inclusion = T0. |
| Correlation of anti-ficolin-3 antibodies with anti-C1q antibodies in SLE patients |
Not provided
165 SLE patients
Inclusion Criteria:
Exclusion Criteria:
Pregnant women
Patient with known evolutive cancer
48 healthy patients matched in age and sex with one or several SLE patients
Not provided
Not provided
SLE patients were studied from medical data files of the Departments of Internal Medicine (Grenoble University Hospital, France) and Nephrology (Conception University Hospital, Marseille, France). For SLE patients, clinical and biological manifestations as well as treatments received and disease activity evaluated using the SLE Disease Activity Index (SLEDAI) at the time of sampling were recorded. SLE patients were divided into subgroups as described in group section.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Chantal DUMESTRE-PERARD, PhD | University Hospital Grenoble, FRANCE | Principal Investigator |
Not provided
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 19208603 | Background | Andersen T, Munthe-Fog L, Garred P, Jacobsen S. Serum levels of ficolin-3 (Hakata antigen) in patients with systemic lupus erythematosus. J Rheumatol. 2009 Apr;36(4):757-9. doi: 10.3899/jrheum.080361. Epub 2009 Feb 4. | |
| 9663482 | Background | Herrmann M, Voll RE, Zoller OM, Hagenhofer M, Ponner BB, Kalden JR. Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum. 1998 Jul;41(7):1241-50. doi: 10.1002/1529-0131(199807)41:73.0.CO;2-H. |
Not provided
Not provided
sub-study still in progress. Further analysis is needed before sponsor can decide his Policy of sharing individual data for this research.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D008180 | Lupus Erythematosus, Systemic |
| D008181 | Lupus Nephritis |
| ID | Term |
|---|---|
| D003240 | Connective Tissue Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D057919 | Biological Oxygen Demand Analysis |
| ID | Term |
|---|---|
| D004784 | Environmental Monitoring |
| D004781 | Environmental Exposure |
| D004787 | Environmental Pollution |
| D011634 | Public Health |
Not provided
Not provided
Not provided
Not provided
Not provided
one serum sample per patient.
This study have a single visit approach with serum collection so every outcome is measured at T0, which is the only visit for the patient. |
| measured at day of inclusion = T0. |
| Correlation of anti-ficolin-3 antibodies with lupus activity (SLEDAI score) in SLE patients | This study have a single visit approach with serum collection so every outcome is measured at T0, which is the only visit for the patient. | measured at day of inclusion = T0. |
| Anti-ficolin-3 antibodies presence in SLE patients with active nephritis | This study have a single visit approach with serum collection so every outcome is measured at T0, which is the only visit for the patient. | measured at day of inclusion = T0. |
| 17469142 | Background | Honore C, Hummelshoj T, Hansen BE, Madsen HO, Eggleton P, Garred P. The innate immune component ficolin 3 (Hakata antigen) mediates the clearance of late apoptotic cells. Arthritis Rheum. 2007 May;56(5):1598-607. doi: 10.1002/art.22564. |
| 20360925 | Background | Liphaus BL, Kiss MH. The role of apoptosis proteins and complement components in the etiopathogenesis of systemic lupus erythematosus. Clinics (Sao Paulo). 2010 Mar;65(3):327-33. doi: 10.1590/S1807-59322010000300014. |
| 25124676 | Background | Orbai AM, Truedsson L, Sturfelt G, Nived O, Fang H, Alarcon GS, Gordon C, Merrill J, Fortin PR, Bruce IN, Isenberg DA, Wallace DJ, Ramsey-Goldman R, Bae SC, Hanly JG, Sanchez-Guerrero J, Clarke AE, Aranow CB, Manzi S, Urowitz MB, Gladman DD, Kalunian KC, Costner MI, Werth VP, Zoma A, Bernatsky S, Ruiz-Irastorza G, Khamashta MA, Jacobsen S, Buyon JP, Maddison P, Dooley MA, Van Vollenhoven RF, Ginzler E, Stoll T, Peschken C, Jorizzo JL, Callen JP, Lim SS, Fessler BJ, Inanc M, Kamen DL, Rahman A, Steinsson K, Franks AG Jr, Sigler L, Hameed S, Pham N, Brey R, Weisman MH, McGwin G Jr, Magder LS, Petri M. Anti-C1q antibodies in systemic lupus erythematosus. Lupus. 2015 Jan;24(1):42-9. doi: 10.1177/0961203314547791. Epub 2014 Aug 14. |
| 9293379 | Background | Yoshizawa S, Nagasawa K, Yae Y, Niho Y, Okochi K. A thermolabile beta 2-macroglycoprotein (TMG) and the antibody against TMG in patients with systemic lupus erythematosus. Clin Chim Acta. 1997 Aug 29;264(2):219-25. doi: 10.1016/s0009-8981(97)00078-8. No abstract available. |
| 21893562 | Background | Sato N, Ohsawa I, Nagamachi S, Ishii M, Kusaba G, Inoshita H, Toki A, Horikoshi S, Ohi H, Matsushita M, Tomino Y. Significance of glomerular activation of the alternative pathway and lectin pathway in lupus nephritis. Lupus. 2011 Nov;20(13):1378-86. doi: 10.1177/0961203311415561. Epub 2011 Sep 5. |
| 15804047 | Background | Kuraya M, Ming Z, Liu X, Matsushita M, Fujita T. Specific binding of L-ficolin and H-ficolin to apoptotic cells leads to complement activation. Immunobiology. 2005;209(9):689-97. doi: 10.1016/j.imbio.2004.11.001. |
| 19109177 | Background | Lacroix M, Dumestre-Perard C, Schoehn G, Houen G, Cesbron JY, Arlaud GJ, Thielens NM. Residue Lys57 in the collagen-like region of human L-ficolin and its counterpart Lys47 in H-ficolin play a key role in the interaction with the mannan-binding lectin-associated serine proteases and the collectin receptor calreticulin. J Immunol. 2009 Jan 1;182(1):456-65. doi: 10.4049/jimmunol.182.1.456. |
| 15147364 | Background | Takahashi R, Tsutsumi A, Ohtani K, Goto D, Matsumoto I, Ito S, Wakamiya N, Sumida T. Anti-mannose binding lectin antibodies in sera of Japanese patients with systemic lupus erythematosus. Clin Exp Immunol. 2004 Jun;136(3):585-90. doi: 10.1111/j.1365-2249.2004.02477.x. |
| D005921 | Glomerulonephritis |
| D009393 | Nephritis |
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D004778 |
| Environment and Public Health |
| D015980 | Public Health Practice |